Literature DB >> 19290933

Fine tuning the immune response with PI3K.

David A Fruman1, Georges Bismuth.   

Abstract

The phosphoinositide 3-kinase (PI3K) family of lipid kinases regulates diverse aspects of lymphocyte behavior. This review discusses how genetic and pharmacological tools have yielded an increasingly detailed understanding of how PI3K enzymes function at different stages of lymphocyte development and activation. Following antigen receptor engagement, activated PI3K generates 3-phosphorylated inositol lipid products that serve as membrane targeting signals for numerous proteins involved in the assembly of multiprotein complexes, termed signalosomes, and immune synapse formation. In B cells, class IA PI3K is the dominant subgroup whose loss causes profound defects in development and antigen responsiveness. In T cells, both class IA and IB PI3K contribute to development and immune function. PI3K also regulates both chemokine responsiveness and antigen-driven changes in lymphocyte trafficking. PI3K modulates the function not only of effector T cells, but also regulatory T cells; these disparate functions culminate in unexpected autoimmune phenotypes in mice with PI3K-deficient T cells. Thus, PI3K signaling is not a simple switch to promote cellular activation, but rather an intricate web of interactions that must be properly balanced to ensure appropriate cellular responses and maintain immune homeostasis. Defining these complexities remains a challenge for pharmaceutical development of PI3K inhibitors to combat inflammation and autoimmunity.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19290933     DOI: 10.1111/j.1600-065X.2008.00750.x

Source DB:  PubMed          Journal:  Immunol Rev        ISSN: 0105-2896            Impact factor:   12.988


  94 in total

1.  The protective effect of myo-inositol on human thyrocytes.

Authors:  Silvia Martina Ferrari; Giusy Elia; Francesca Ragusa; Sabrina Rosaria Paparo; Claudia Caruso; Salvatore Benvenga; Poupak Fallahi; Alessandro Antonelli
Journal:  Rev Endocr Metab Disord       Date:  2018-12       Impact factor: 6.514

2.  Combination of temsirolimus (CCI-779) with chemoradiation in newly diagnosed glioblastoma multiforme (GBM) (NCCTG trial N027D) is associated with increased infectious risks.

Authors:  Jann N Sarkaria; Eva Galanis; Wenting Wu; Allan B Dietz; Timothy J Kaufmann; Michael P Gustafson; Paul D Brown; Joon H Uhm; Ravi D Rao; Laurence Doyle; Caterina Giannini; Kurt A Jaeckle; Jan C Buckner
Journal:  Clin Cancer Res       Date:  2010-10-04       Impact factor: 12.531

Review 3.  Lipid-based patterning of the immunological synapse.

Authors:  Morgan Huse
Journal:  Biochem Soc Trans       Date:  2014-12       Impact factor: 5.407

Review 4.  Development of phosphoinositide-3 kinase pathway inhibitors for advanced cancer.

Authors:  James M Cleary; Geoffrey I Shapiro
Journal:  Curr Oncol Rep       Date:  2010-03       Impact factor: 5.075

Review 5.  Toll-like receptors and B-cell receptors synergize to induce immunoglobulin class-switch DNA recombination: relevance to microbial antibody responses.

Authors:  Egest J Pone; Hong Zan; Jingsong Zhang; Ahmed Al-Qahtani; Zhenming Xu; Paolo Casali
Journal:  Crit Rev Immunol       Date:  2010       Impact factor: 2.214

Review 6.  The LAT story: a tale of cooperativity, coordination, and choreography.

Authors:  Lakshmi Balagopalan; Nathan P Coussens; Eilon Sherman; Lawrence E Samelson; Connie L Sommers
Journal:  Cold Spring Harb Perspect Biol       Date:  2010-07-07       Impact factor: 10.005

7.  T regulatory cells maintain intestinal homeostasis by suppressing γδ T cells.

Authors:  Sung-Gyoo Park; Ramkumar Mathur; Meixiao Long; Namiko Hosh; Liming Hao; Matthew S Hayden; Sankar Ghosh
Journal:  Immunity       Date:  2010-11-11       Impact factor: 31.745

Review 8.  Molecular underpinning of B-cell anergy.

Authors:  Yuval Yarkoni; Andrew Getahun; John C Cambier
Journal:  Immunol Rev       Date:  2010-09       Impact factor: 12.988

9.  Interleukin-7 is required for CD4(+) T cell activation and autoimmune neuroinflammation.

Authors:  Brian R Lawson; Rosana Gonzalez-Quintial; Theodoros Eleftheriadis; Michael A Farrar; Stephen D Miller; Karsten Sauer; Dorian B McGavern; Dwight H Kono; Roberto Baccala; Argyrios N Theofilopoulos
Journal:  Clin Immunol       Date:  2015-08-25       Impact factor: 3.969

10.  Biased binding of class IA phosphatidyl inositol 3-kinase subunits to inducible costimulator (CD278).

Authors:  Yenny Y Acosta; Maria Paz Zafra; Gloria Ojeda; Ilaria Seren Bernardone; Umberto Dianzani; Pilar Portolés; Jose M Rojo
Journal:  Cell Mol Life Sci       Date:  2010-12-28       Impact factor: 9.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.